ARCHIVES

In Brief: Armitage Appointed to NCAB; UT Board Approves New Clinical Building for MDACC

This article is from The Cancer Letter archive.

Vol. 26 No. 20 | May 19, 2000

Download PDF Visit The Full Archive

Related Articles

ACS Board Accepts Hammer’s ffer, Will Support Construction Survey

February 17, 1984

Phase II Elotuzumab Study Demonstrates 33 Months PFS

July 26, 2013

Appeals Court Overturns FDA Approval Of Generic Paclitaxel, A Setback For Ivax.

November 9, 2001

Platinum-Free Break Enhances Therapy After First Relapse In Ovarian Cancer

March 28, 2003

IDMC Recommends Halting Phase III Trial Of Onartuzumab in MET-Positive NSCLC

March 28, 2014

Clinical Trials Approved By NCI CTEP Last Month

September 30, 2011